This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
IntroductionCerebrovascular disease (CVD), particularly carotid artery atherosclerosis, contributes substantially to global morbidity and mortality. The ability to precisely detect atherosclerosis is crucial, as it directly influences patient management, including decisions regarding surgical interventions.
We appreciate the American Medical Association’s decision to assign FFRCT a Category I CPT code, a decision backed by years of research that highlights the positive impact FFRCT can have on the diagnosis and eventually treatment of patients with coronary artery disease,” said John Farquhar , CEO of HeartFlow.
A jam-packed, expertly curated agenda will highlight the latest and most impactful advancements in cardiorenal metabolic medicine and protocols for future-focused, whole-patientcare. Michos, MD, MHS, FACC, FAHA, FASE, FASPC ; famed hypertension expert Keith C. Ferdinand, MD , ‘Boston Magazine’s 2021 Top Doctor’ Deepak L.
Keynote speaker and atherosclerosis expert Peter Libby, MD , captivated the audience with an update on his research into inflammation and atherosclerosis. He discussed therapeutic options not only for treating atherosclerosis but also for preventing cardiovascular disease.
Boettcher II Endowed Chair in atherosclerosis research at the University of Colorado School of Medicine Anschutz Medical Campus, director of the Lipid Clinic at University of Colorado Hospital, and program director of the National Center for Research Resources at the Colorado Clinical Translational Sciences Institute.
Acclaimed Cardiology Expert Dr. Peter Libby To Keynote 19th Annual CMHC Dr. Libby will provide an update on his groundbreaking research on inflammation and atherosclerosis, offering practical clinical approaches. Shapiro, DO Back By Popular Demand! Contact Data Megan Magana, Sr.
The Dyslipidemia/Atherosclerosis/Thrombosis track will feature sessions on dyslipidemia and LDL cholesterol, including: LDL Lowering Therapy Beyond Statins Supported by an educational grant from Esperion Therapeutics.
One promising strategy is the formation of creative partnerships between patients and their healthcare teams. We can revolutionize patientcare and significantly reduce cardiometabolic risk by fostering collaborative relationships and leveraging diverse expertise and experiences.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
40 
Let's personalize your content